Drug Detail:Molindone (Molindone [ moe-lin-done ])
Drug Class: Miscellaneous antipsychotic agents
Usual Adult Dose for Schizophrenia
Initial Dosing Schedule:
- Recommended dose: 50 to 75 mg orally per day, increasing the dose to 100 mg/day in 3 to 4 days
- Maximum dose: 225 mg/day
Maintenance Dosing Schedule:
- Mild symptomology: 5 to 15 mg orally 3 to 4 times a day
- Moderate symptomology: 10 to 25 mg orally 3 to 4 times a day
- Severe symptomology: Up to 225 mg/day
Comments:
- Patients with severe symptomology may require 225 mg/day.
- Elderly and/or debilitates patients should begin on the lower dosage.
Use: Management of schizophrenia
Usual Pediatric Dose for Schizophrenia
12 to 18 years:
Initial Dosage Schedule:
- Recommended dose: 50 to 75 mg orally per day, increasing the dose to 100 mg/day in 3 to 4 days
- Maximum dose: 225 mg/day
Maintenance Dosing Schedule:
- Mild symptomology: 5 to 15 mg orally 3 to 4 times a day
- Moderate symptomology: 10 to 25 mg orally 3 to 4 times a day
- Severe symptomology: Up to 225 mg/day
Comments:
- Patients with severe symptomology may require 225 mg/day.
- Debilitated patients should begin on the lower dosage.
Use: Management of schizophrenia
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
US BOXED WARNING:
- INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: This drug has an increased risk of mortality when administered to elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. This drug is not approved for use in patients with dementia-related psychosis.
Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- See manufacturer product information.
Storage requirements:
- See manufacturer product information.
General:
- Effectiveness was determined in clinical studies with newly hospitalized and chronically hospitalized, acutely ill patients with schizophrenia.
- This drug has not been shown effective in the management of behavioral complications in patients with mental impairment.
Monitoring:
- Complete blood count before and periodically during treatment
Patient advice:
- Warn patients to avoid abrupt discontinuation of this drug.
- Tell patients to immediately report any signs/symptoms of neutropenia/leukopenia, neuroleptic malignant syndrome, or tardive dyskinesia.
- Patients should be advised to report all concurrent prescription and nonprescription medications or herbal products they are taking.
- Inform patients that this drug may cause drowsiness, and they should avoid driving or operating machinery until the full effects of the drug are known.
- Patients should be advised to speak to a healthcare provider if they are pregnant, intend to become pregnant, or are breastfeeding.
